TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02389153

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: collaborative care CHD
Description: Over a time span of 6 months participants receive individualized treatment to reduce risk factors and improve quality of life, based on their preferences following a health plan, which they developed with their health coach.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: collaborative care CHD
Description: Over a time span of 6 months participants receive individualized treatment to reduce risk factors and improve quality of life, based on their preferences following a health plan, which they developed with their health coach.
Study: NCT04028401

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5% benzoyl peroxide
Description: Application of 5% benzoyl peroxide during 5 days before the procedure
Study: NCT00606437

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total Body Irradiation with Fludarabine in UCB Transplants
Description: Administration of the preparative regimen, infusion of the stem cell graft, inpatient care during the immediate post-transplant period and outpatient follow-up for the first 3 months after transplant and at 6, 12, 24 and 36 months. Patients will have human leukocyte antigen (HLA) serologic typing and DNA typing. Bags of UCB are thawed, and diluted by 1:1 volume using a 5% albumin/dextran solution. The thawed and diluted umbilical cord blood unit (UCBU) is next weighed and centrifuged. Specimens are obtained for cell count and viability, culture, clonogenic assays, and phenotype. The UCB is infused at a rate of 1-3 ml/min. Furosemide (0.5-1.0 mg/kg/dose) may be given if volume overload or decreased urine output occurs. Each UCB infusion shall be tested for sterility, CFU content, number of CD34+ cells, cell count and viability.
Study: NCT00782847

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: DiaNe consultation and support program
Description: the DiaNe consultation and support program for clients with diabetic nephropathy consists of 4 sessions at 90-120 minutes conducted every week in a period of 4 weeks
Study: NCT04615052

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: A 16 weeks parallel-group randomised controlled trial will be performed, in which covid-19 survivors patients will complete a telemonitored home-based exercise training program, 3 times per week. The training program will involve strength, aerobic, balance and flexibility exercises.
Study: NCT03517397

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile Contingency Management
Description: Participants will be offered 6 counseling sessions, nicotine replacement therapy, and a smartphone app that remotely verifies participant identity and smoking abstinence and automatically credits a gift card account for evidence of smoking abstinence.
Study: NCT02483962

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Gelatine capsule
Description: Gelatine capsules containing no active ingredients.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Venavine Intensive®
Description: Gelatine capsules containing 360 mg red vine leaf extract, 60 mg of horse chestnut extract, 35 mg of butchers broom extract and 3,2 mg of vitamin B6.
Study: NCT01469377

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo was supplied in capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cariprazine
Description: Cariprazine was supplied in capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cariprazine
Description: Cariprazine was supplied in capsules.
Study: NCT03346694

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Island Dressing
Description: participant randomized to control group before end of surgery to be applied on cardiovascular heart surgical sternal incision.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Prevena Negative Pressure wound dressing
Description: participant randomized to dressing before end of surgery to be applied on cardiovascular heart surgical sternal incision.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mepilex Border Post-Op Ag
Description: Participant randomized to dressing before end of surgery to be applied on cardiovascular heart surgical sternal incision
Study: NCT02668536

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Sunscreen
Description: Areas will be treated with a standard preparation, consisting of padimate O (7%) and oxybenzone (3%) will be used as the control sunscreen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard Sunscreen
Description: Areas will be treated with a standard preparation, consisting of padimate O (7%) and oxybenzone (3%) will be used as the control sunscreen.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: BNP
Description: Additional areas will be treated with empty bioadhesive nanoparticles (BNPs).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BNP
Description: Additional areas will be treated with empty bioadhesive nanoparticles (BNPs).
Study: NCT03566485

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given by IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given by IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: Given by mouth

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idasanutlin
Description: Given by mouth
Study: NCT04059159

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Connected Catheter
Description: Patients will use the Connected Catheter to empty the bladder during the course of treatment.
Study: NCT04957875

Intervention type: DEVICE
Intervention: emergency endoscopic therapy
Description: When cirrhotic patients presented with AVB to the emergency department, emergency physicians consulted gastroenterologists on duty to assess the patient for suitability for endoscopy, usually after initial stabilization. Performance of endoscopy and its timing was at the discretion of the gastroenterologist on call. Therapeutic endoscopy for AVB was performed within 24 hours after consultation by an experienced attending endoscopist, using standard forward-viewing upper gastrointestinal video endoscopes at individual centers. Written informed consent for endoscopy was obtained before each procedure. The standard of care at all hospitals was to administer a vasoactive agent and antibiotics upon the patient's presentation. Packed red blood cells were transfused at the discretion of the attending gastroenterologist.

Intervention type: DEVICE
Intervention: emergency endoscopic therapy
Description: When cirrhotic patients presented with AVB to the emergency department, emergency physicians consulted gastroenterologists on duty to assess the patient for suitability for endoscopy, usually after initial stabilization. Performance of endoscopy and its timing was at the discretion of the gastroenterologist on call. Therapeutic endoscopy for AVB was performed within 24 hours after consultation by an experienced attending endoscopist, using standard forward-viewing upper gastrointestinal video endoscopes at individual centers. Written informed consent for endoscopy was obtained before each procedure. The standard of care at all hospitals was to administer a vasoactive agent and antibiotics upon the patient's presentation. Packed red blood cells were transfused at the discretion of the attending gastroenterologist.
Study: NCT00566696

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CliniMACS
Description: Miltenyi Biotec CliniMACS stem cell selection device

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem cell transplantation
Description: An infusion of HLA mismatched family member donor stem cells processed through the use of the investigational Miltenyi Biotec CliniMACS device.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Transplant recipients will receive a conditioning regimen consisting of systemic chemotherapy and antibodies.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thioplex®
Description: Transplant recipients will receive a conditioning regimen consisting of systemic chemotherapy and antibodies.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-phenylalanine mustard
Description: Transplant recipients will receive a conditioning regimen consisting of systemic chemotherapy and antibodies.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Description: Transplant recipients will receive a conditioning regimen consisting of systemic chemotherapy and antibodies.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituxan™
Description: Transplant recipients will receive a conditioning regimen consisting of systemic chemotherapy and antibodies.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Description: After January 2010, due to the unavailability of muromonab, transplant recipients received a conditioning regimen consisting of systemic chemotherapy and antibodies, including alemtuzumab.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Transplant recipients will receive a conditioning regimen consisting of systemic chemotherapy and antibodies.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-thymocyte globulin (Rabbit)
Description: Transplant recipients will receive a conditioning regimen consisting of systemic chemotherapy and antibodies.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: Transplant recipients will receive a conditioning regimen consisting of systemic chemotherapy and antibodies.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Muromonab
Description: Prior to January 2010, transplant participants received a conditioning regimen consisting of systemic chemotherapy and antibodies, including muromonab. Muromonab became unavailable from the manufacturer at that time and was replaced by alemtuzumab.
Study: NCT03553303

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacubitril / Valsartan Oral Tablet
Description: Increasing doses of Sacubitril/Valsartan
Study: NCT02143388

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IMRT combine with cisplatin concurrent chemotherapy
Description: Patients in the control arm received radical radiotherapy with IMRT, and cisplatin (100mg/m2 on day 1) every three weeks for three cycles during RT.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMRT combine with cisplatin concurrent chemotherapy plus capecitabine adjuvant chemotherapy
Description: Patients in the experimental arm received radical radiotherapy with IMRT, and cisplatin (100mg/m2 on day 1) every three weeks for three cycles during RT,followed by adjuvant chemotherapy with oral capecitabine(1000mg/m2/ twice a day for 14 days)every three weeks for eight cycles.
Study: NCT02321709

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR113244
Description: Pharmaceutical form:solution for injection Route of administration: subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR113244
Description: Pharmaceutical form:solution for injection Route of administration: subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR113244
Description: Pharmaceutical form:solution for injection Route of administration: subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Pharmaceutical form:solution for injection Route of administration: subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Pharmaceutical form:solution for injection Route of administration: subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Pharmaceutical form:solution for injection Route of administration: subcutaneous
Study: NCT03369262

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OBE022
Description: Oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebos
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atosiban
Description: I.V.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atosiban
Description: I.V.
Study: NCT04859933

Intervention type: PROCEDURE
Intervention: AV-node isolation
Description: Abaltion performed in the right atrium isolating the AV-node from the atrium

Intervention type: PROCEDURE
Intervention: AV-node ablation
Description: Right sided ablation of the AV-node
Study: NCT01847027

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NutraStem
Description: Determine whether NutraStem® in combination with an exercise stimulus will cause increased human peripheral blood sample levels of CD34+ and CD133+ adult stem cells and whether these stem cells display more protection against oxidative stress.~Determine whether NutraStem® in combination with an exercise stimulus will cause increased human peripheral blood sample levels of CD34+ and CD133+ adult stem cells and whether these stem cells display more protection against oxidative stress.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Determine whether NutraStem® in combination with an exercise stimulus will cause increased human peripheral blood sample levels of CD34+ and CD133+ adult stem cells and whether these stem cells display more protection against oxidative stress.
Study: NCT00773214

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: 12-week supervised exercise programme (5 times /week at 75% maximal Heart Rate)
Study: NCT00611026

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tolterodine ER
Description: The tolterodine treatment will be 4 mg once daily(QD) for 12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo treatment will be once daily(QD) for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fesoterodine
Description: The fesoterodine treatment will start with 4 mg once daily(QD) for 1 week followed by a forced dose-escalation to 8mg once daily(QD) for 11 weeks.
Study: NCT04338802

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nintedanib 150 MG
Description: Nintedanib cloth sulfonate 150 mg, twice a day, about 12 hours apart. Continuous medication for 8 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Empty capsules with the same appearance and ingredients as Nidanib soft capsules: one capsule at a time, twice a day, with an interval of about 12 hours each time. Continuous medication for 8 weeks.
Study: NCT01310075

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Alloderm
Description: 6 x 12 cm piece or 6 x 16 cm piece is trimmed into a semicircle and sewn into the inframammary fold using vicryl. The smooth side is placed against the implant.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Surgimend
Description: 10 x 15 cm piece of fenestrated material is sewn to the fold, curved side along the fold, using vicryl suture.
Study: NCT03154411

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABY-029
Description: A minimum of 6 and a maximum of 12 adult patients with a diagnosis of primary soft-tissue sarcoma will be enrolled. Initial diagnostic biopsy specimens will be analyzed for EGFR positivity (an EGFR pathology score ≥ 1) by immunohistochemistry following routine diagnostic processing by Pathologist. Patients will be administered a single intravenous dose of ABY-029 1-3 hours before surgery.
Study: NCT04724109

Intervention type: DRUG
Intervention: Equfina
Description: Equfina oral tablets.
Study: NCT04240548

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Regional Nodal Irradiation
Study: NCT02502617

Intervention type: DIETARY_SUPPLEMENT
Intervention: medical nutrition
Description: The participants are expected to improve their body weight with 10-30% during a closely monitored inpatient-treatment comprising nutritional rehabilitation.
Study: NCT01879098

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic: Bacillus subtilis
Description: Bacillus subtilis will be taken as a capsule once daily for 6 weeks by subjects in the group receiving this supplement (group is unknown, double-blinded).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus plantarum
Description: Lactobacillus plantarum will be taken as a capsule once daily for 6 weeks by subjects in the group receiving this supplement (group is unknown, double-blinded).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bifidobacterium animalis
Description: Bifidobacterium animalis will be taken as a capsule once daily for 6 weeks by subjects in the group receiving this supplement (group is unknown, double-blinded).

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be taken once daily for 6 weeks by every subject at some point in the study (crossover design).
Study: NCT00467753

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxcarbazepine
Description: Oxcarbazepine is available in a 300mg/5ml solution. Dosage will start at 150 mg (2.5ml) at night for 3 days and will be increased to 150 mg in the am and pm. For children who are able to tolerate the 150 mg BID dose, the oxcarbazepine will be increased to 300 mg at night and 150 mg in the morning for 3 days and 300 mg BID for the next week. The children will remain on this dose until week 3, at which time if they are tolerating the medication and do not have a Clinical Global Improvement Scale (CGI) of 1 (very much improved) they will be increased to 600 mg twice a day in a method similar to the above increases. After week 4, the child will remain on the same stable dose.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo/sugar pill
Description: Dosage similar to active drug
Study: NCT02185482

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physician Supported Care

Intervention type: OTHER
Group type: OTHER
Intervention: Usual care
Study: NCT04436848

Intervention type: OTHER
Intervention: This is a non-interventional study
Description: This is a non-interventional study

Intervention type: OTHER
Intervention: This is a non-interventional study
Description: This is a non-interventional study

Intervention type: OTHER
Intervention: This is a non-interventional study
Description: This is a non-interventional study
Study: NCT01583296

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Music Relaxation Therapy (MRT)
Description: music relaxation therapy and breathing at resting respiration rate

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT and HRVB
Description: cognitive behavioral therapy and heart rate variability biofeedback
Study: NCT02111304

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: iOWH032

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: iOWH032
Study: NCT03929497

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AF11167
Description: Lu AF11167 - 2 or 4 mg/day; tablets, orally
Study: NCT02106858

Intervention type: DRUG
Intervention: Regorafenib (Stivarga,BAY73-4506)
Description: Patients treated by Physician with Stivarga under approved local prescriptions
Study: NCT00267566

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Strongest Families (formerly Family Help Program): Anxiety Program
Description: Evidence-based psychological and behavioural distance intervention

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Strongest Families (formerly Family Help Program): Anxiety Program
Description: Evidence-based psychological and behavioural distance intervention
Study: NCT03612752

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: CMI-168
Description: Dietary supplement

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT03117140

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine 0.75%
Description: Only ropivacaine 0.75% is administered for this arm of the interscalene block

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.75% + 300 mcg Buprenorphine
Description: Ropivacaine 0.75% + 300 mcg Buprenorphine is administered for this arm of the interscalene block

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.75% + 75 mcg clonidine
Description: Ropivacaine 0.75% + 75 mcg Clonidine is administered for this arm of the interscalene block

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.75% + 8 mg dexamethasone
Description: Ropivacaine 0.75% + 8 mg Dexamethasone is administered for this arm of the interscalene block
Study: NCT03186742

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eplerenone 50 mg Tab
Description: Eplerenone 50 mg Tab once a day
Study: NCT02533453

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bydureon
Description: exenatide once weekly
Study: NCT04041167

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: alpha lipoic acid
Description: alpha lipoic acid treatment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: No alpha lipoic acid treatment
Study: NCT01732237

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-42396302
Description: A single dose of JNJ-42396302 100 micrograms (1 mL) will be administered orally with 240-mL non-carbonated water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-42692507
Description: A single dose of JNJ-42692507 100 micrograms (1 mL) will be administered orally with 240-mL non-carbonated water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-53773187
Description: A single dose of JNJ-53773187 100 micrograms (1 mL) will be administered orally with 240-mL non-carbonated water.
Study: NCT02512029

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-AV-1451

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-AV-1451
Study: NCT03599219

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: sample
Description: confirmation of platelet dysfunction

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: sample
Description: confirmation of platelet dysfunction
Study: NCT01075542

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AcrySof Toric intraocular lens, model SN60TT
Description: The lens is made of foldable acrylic material and is implanted in the capsular bag

Intervention type: DEVICE
Group type: OTHER
Intervention: AcrySof Monofocal IOL, model SN60AT
Description: The lens is made of foldable acrylic material and is implanted in the capsular bag